NASDAQ:MLTX 29 September 2025 - 8 January 2026

MoonLake Immunotherapeutics shares plunged about 85% pre-market Monday after mixed Phase 3 VELA trial results, dropping from around $62 to under $8 and cutting market cap from $3.9 billion to $0.5 billion. The stock had surged days earlier on takeover rumors and clinical optimism. VELA-1 met its primary endpoint, but VELA-2 narrowly missed. Analyst sentiment turned sharply negative after the data release.